AccessibilityHelp
Minerva Surgical logo

Minerva Surgical(OTC) UTRS

Market Cap$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Minerva Surgical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-19
Minerva Surgical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-01
1 month+0%USD 0.002026-09-14
3 month+9,900%USD 0.002026-07-06
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-10-13
3 year-100%USD 3.002023-10-20
Since inception-100%USD 180.002021-10-22

Minerva Surgical Financials at a Glance

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$51.69M

Net Income (TTM)

-$35.55M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1628.06 (High)

Price

$0.00

Volume

51

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Aug 31, 2026

UTRS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Minerva Surgical

Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing innovative, minimally invasive solutions for women's uterine healthcare needs. The company offers a range of advanced medical devices designed to improve patient outcomes and enhance the efficiency of healthcare providers.

Products and Services
  • Minerva ES and Genesys HTA endometrial ablation systems
  • Symphion Tissue Removal System for uterine tissue removal
  • Resectr Tissue Resection Device for hysteroscopic procedures
Growth Outlook
  • Revenue of $11.97 million in Q3 2023, showing consistent demand
  • Gross profit margin of 52% in Q3 2023, indicating operational efficiency
  • Strong product pipeline aimed at expanding market share in women's health
Financial Highlights
  • Net income of -$7.18 million in Q3 2023, reflecting ongoing investment in growth
  • Cash and cash equivalents of $11.43 million as of September 30, 2023
  • Current ratio of 2.53, indicating strong short-term financial health
Minerva Surgical, Inc. operates in the medical devices sector, specifically targeting the needs of women’s healthcare. The company has developed a suite of products that are utilized by healthcare professionals in various clinical settings, including hospitals and outpatient surgical centers. The focus on minimally invasive techniques aligns with current trends in healthcare, emphasizing patient comfort and quicker recovery times. The growth outlook for Minerva Surgical appears promising, with recent revenue figures indicating a solid market presence. The gross profit margin suggests that the company is managing its costs effectively while maintaining a competitive edge in product offerings. The current ratio indicates that the company is well-positioned to meet its short-term obligations, which is a positive sign for potential investors. Despite reporting a net loss, the ongoing investments in research and development signal a commitment to innovation and long-term growth. The cash reserves provide a buffer for operational needs and future expansion. Overall, Minerva Surgical, Inc. presents an intriguing opportunity within the medical technology landscape, particularly for those interested in the evolving field of women's health.
AI Generated • Oct 6, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

174

CEO

David M. Clapper

Website

minervasurgical.com

Headquarters

Santa Clara, CA 95054, US

UTRS Financials

Key Financial Metrics (TTM)

Gross Margin

54.17%

Operating Margin

-61.44%

Net Income Margin

-67.83%

Return on Equity

-111.32%

Return on Capital

-54.33%

Return on Assets

-49.51%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.88M

Volume

51

Avg. Volume

30.846

Financials (TTM)

Gross Profit

$28.01M

Operating Income

-$29.26M

EBITDA

-$20.31M

Operating Cash Flow

-$38.73M

Capital Expenditure

-$69.00K

Free Cash Flow

-$38.80M

Cash & ST Invst.

$11.13M

Total Debt

$43.55M

Minerva Surgical Performance Analysis

Minerva Surgical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 52,103,000N/A
20222022-12-31USD 50,294,000-3.5%
Minerva Surgical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-319.7%
Q12023-03-31-9.2%
Q22023-06-306.8%
Q32023-09-30-10.6%
Minerva Surgical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -14.89N/A
20222022-12-31USD -23.6859.0%
Minerva Surgical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-3174.6%
Q12023-03-31-39.8%
Q22023-06-3065.1%
Q32023-09-3017.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$11.97M

-4.9%

Gross Profit

$6.22M

-8.7%

Gross Margin

51.97%

N/A

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.17

N/A

Employees

174

N/A

Net Income

-$7.18M

+36.6%

EBITDA

-$4.56M

+41.4%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$11.13M

-26.4%

Total Debt

$43.55M

+9.3%

Accounts Receivable

$7.57M

+11.5%

Inventory

$18.18M

+6.9%

Long Term Debt

$31.28M

-20.4%

Short Term Debt

$12.27M

+2072.0%

Return on Assets

-49.51%

N/A

Return on Invested Capital

-56.57%

N/A

Free Cash Flow

-$5.11M

+24.9%

Operating Cash Flow

-$5.10M

+25.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ETAOFEtao International Co., Ltd.
$0.00+0.00%
FOXOFOXO Technologies Inc.
$0.10+2.03%
RNAZTransCode Therapeutics, Inc.
$1.72-2.84%
AKANAkanda Corp.
$1.03+1.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$11.98-21.01%
EWZiShares - iShares Msci Brazil ETF
$32.84-22.90%
ITUBItaú Unibanco
$7.36-23.91%
XPXP
$14.93-50.90%

Questions About UTRS

What is the current price of Minerva Surgical?

Minerva Surgical is trading at $0.00 per share.

What is the 52-week range for Minerva Surgical?

Over the past 52 weeks, Minerva Surgical has traded between $0.00 and $0.00.

How much debt does Minerva Surgical have?

As of the most recent reporting period, Minerva Surgical reported total debt of $39.69M.

How much cash does Minerva Surgical have on hand?

Minerva Surgical reported $7.55M in cash and cash equivalents in its most recent financial results.

What is Minerva Surgical’s dividend yield?

Minerva Surgical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services